Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline Review, H1 2020’, provides an overview of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )

– The report reviews pipeline therapeutics for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) therapeutics and enlists all their major and minor projects

– The report assesses Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ArmaGen Inc

BioStrategies LC

bluebird bio Inc

EdiGene Inc

Eloxx Pharmaceuticals Inc

GT Gain Therapeutics SA

Immusoft Corp

JCR Pharmaceuticals Co Ltd

Jupiter Orphan Therapeutics Inc

Magenta Therapeutics Inc

Orchard Therapeutics Plc

Ossianix Inc

Paradigm Biopharmaceuticals Ltd

RegenxBio Inc

ReqMed Co Ltd

Sangamo Therapeutics Inc

Sigilon Therapeutics Inc

Tamid Bio Inc

Tega Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Overview

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Therapeutics Development

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Therapeutics Assessment

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Companies Involved in Therapeutics Development

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Drug Profiles

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Dormant Projects

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Discontinued Products

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by ArmaGen Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by BioStrategies LC, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by bluebird bio Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by EdiGene Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Eloxx Pharmaceuticals Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by GT Gain Therapeutics SA, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Immusoft Corp, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by JCR Pharmaceuticals Co Ltd, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Jupiter Orphan Therapeutics Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Magenta Therapeutics Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Orchard Therapeutics Plc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Ossianix Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by RegenxBio Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by ReqMed Co Ltd, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Sangamo Therapeutics Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Sigilon Therapeutics Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Tamid Bio Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Pipeline by Tega Therapeutics Inc, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Dormant Projects, H1 2020

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports